Scholars Central

Research articlePublished 2013

Commercial Abuse-Deterrent Dosage Forms: Clinical Status

Authors: David J Mastropietro, Hossein Omidian

Journal of Developing Drugs

Volume 2 · Issue 1 · Pages 1–6

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Abuse of prescription medications is being combated with the advent of novel formulations designed to prevent or discourage tampering and misuse. The ability of these abuse-deterrent and tamper-resistant formulations to impact abuse, and the test methods used to determine their lowered abuse potential is becoming more important. There are three main reasons for the need to access these formulations, a) to determine if a formulation itself can impact abuse of a product, b) for standardized methods that can be used to support product labeling, and c) to evaluate both new and generic products for tamper-equivalence. The object of this review is to provide an overview and evaluation of the various types of premarketing tamper and abuse studies performed both in-vitro and by experienced abusers when evaluating a product’s deterrence to abuse. To find and assess abuse liability studies of FDA approved products, a database search using Medline and Google Scholar with keywords “abuse deterrent”, and “tamper resistant” was used along with information obtained from product innovator websites and regulatory documents from the FDA regarding each product. Results from our investigation revealed that studies evaluating of a products abuse deterrent properties could be separated into three main categories based on the state the product is in during the study. The three main categories are 1) solid state studies, 2) solution state studies, and 3) aerosol state studies. For each category, various study examples are discussed and assessed for factors that will have significant impact on the way the study is evaluated.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Developing Drugs.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “David J Mastropietro”
  • BylineArticles whose byline prints “Hossein Omidian”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels